

Abattis Amends Certain Warrants

Vancouver, BC – September 12, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTFB) (CSE: ATT), announces that today the Company is repricing certain warrants issued pursuant to a private placement on March 17, 2015. The Company will amend the following terms:

	Original Terms	Revised Terms
Exercise Price	\$0.18 per common share	\$0.15 per common share
Term	September 19, 2016 at 5:00 PM	September 19, 2018 at 5:00 PM

At total of 2,365,072 warrants were issued under the private placement and are subject to amendment. Pursuant to Policy 7.4.6 of the Canadian Stock Exchange, insiders do not comprise more than 10% of the warrants subject to amendment and therefore no pro-rata adjustment is necessary.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Rene David"

Rene David, CFO/COO and interim CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.